News
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
February 05, 2024
-
October 26, 2023
-
October 28, 2022
-
March 09, 2022--Company Announces Revisions Intended to Optimize CM-101 Clinical Development Program and Produce More Informative Data, More Rapidly and Efficiently; Changes Also Expected to Extend Cash Runway through End of 2023--
-
January 04, 2022- Company Also Announces Move to an Expanded Scientific and Business Facility in Israel
-
December 03, 2021- Dr. Weiner Brings Chemomab Extensive Biotechnology and Pharmaceutical Industry R&D and Strategic Experience, Including Overseeing the Design and Management of Clinical Trials for Rare and Challenging Therapeutic Indications
-
December 02, 2021--First U.S. IND Enables Increase in the Number of Clinical Sites for Chemomab's Ongoing Phase 2 SPRING Trial--
-
Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate UpdateNovember 12, 2021Expands Senior Management Team While Advancing Two Independent Phase 2 Trials and Preparing to Initiate a Third in Early 2022
-
November 10, 2021--New Preclinical Data Further Supports Ability of CM-101 to Break the Vicious Cycle of Inflammation and Fibrosis in Primary Sclerosing Cholangitis--
-
November 08, 2021Seasoned veteran brings Chemomab three decades of diverse life sciences industry experience
-
October 26, 2021Live Event featuring Dr. Dinesh Khanna to be Held Wednesday, November 3rd from 10:00 am - 11:00 am ET
-
September 27, 2021-Collaboration will study how CCL24, a soluble protein involved in profibrotic and proinflammatory processes, contributes to the vascular damage related to systemic sclerosis (SSc)-
-
September 02, 2021Dr. Adi Mor continues as Chief Scientific Officer, directing scientific strategy and overseeing R&D operations
-
September 01, 2021
-
Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business UpdateAugust 13, 2021- CM-101 Phase 2a trials in PSC and liver fibrosis continue to enroll patients with data expected in 2022 -
-
June 23, 2021AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility
-
May 13, 2021Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients
-
April 26, 2021The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation
-
March 16, 2021Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol "CMMB"
-
March 15, 2021Anchiano shareholders approve all resolutions at shareholder meeting
-
February 02, 2021- CM-101 is a first in class CCL24 blocking antibody, that showed a positive safety and tolerability profile in phase I studies and first line evidence of anti-fibrotic activity in a phase Ib study in NAFLD patients
-
January 05, 2021- CM-101, a first in class CCL24 blocking antibody, showed excellent safety and tolerability using both IV and SC administration
-
December 15, 2020Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need
-
February 19, 2020- CM-101 composition of matter patent was issued by US, Japan and China Patent and Trademark Offices (patents 10,246,508, 10,479,830, 6553075, ZL 201580011755.4)
-
Chemomab announces a peer reviewed publication of preclinical proof of concept data supporting the pivotal role of CCL24 in systemic sclerosis and idiopathic pulmonary fibrosis. The paper “Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis” was published in “Annals of Rheumatoid Diseases”January 02, 2020
-
August 21, 2019CM-101 was safe and well tolerated using both IV and SC formulations
-
Chemomab announces a peer reviewed publication of preclinical proof of concept data supporting the pivotal role of CCL24 in systemic sclerosis and idiopathic pulmonary fibrosis. The paper “Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis” was published in May 2019 edition of “Annals of Rheumatoid Diseases” and supports the therapeutic potential of CM-101 for the treatment of patients with Systemic Sclerosis. Annals of Rheumatoid Diseases is a top line peer reviewed journal which publishes basic, clinical and translational novel scientific research, owned by the European League Against Rheumatism (EULAR) and BMJ.April 30, 2019
-
December 04, 2018
-
November 30, 2018
-
December 04, 2017SBI Japan-Israel Innovation Fund and Milestone Participate in Investment Round